Please login to the form below

breakthrough designation

This page shows the latest breakthrough designation news and features for those working in and with pharma, biotech and healthcare.

FDA green lights BMS’ multiple myeloma combo

FDA green lights BMS’ multiple myeloma combo. Speedy approval follows a breakthrough designation. ... Now, after a breakthrough designation, BMS has gained approval of Empliciti as part of a new combination known as EPd.

Latest news

AZ and Clovis PARP inhibitors show their mettle at ESMO

Rubraca picked up a breakthrough designation from the FDA in prostate cancer earlier this year, and has said it hopes to be in a position to file for approval in the
Pfizer’s Prevnar-13 successor takes aim at Merck rival

Pfizer just got a leg-up in its race with Merck &Co to bring a new-generation pneumococcal vaccine to the US market after getting a breakthrough designation (BTD) for its
J&J files ‘breakthrough’ bladder cancer drug in US

J&J files ‘ breakthrough’ bladder cancer drug in US. Needed as most patients don't respond to checkpoint inhibitors. ... Erdafitinib (JNJ-42756493) picked up a breakthrough designation (BTD) from the FDA earlier this year, so should benefit from a
New data keeps AbbVie’s star pipeline therapies on track

Upadacitinib is already in a phase III trial in atopic dermatitis and picked up a breakthrough designation (BTD) from the FDA for this indication earlier this year.
FDA awards another non-opioid pain drug breakthrough status

The US regulator yesterday awarded Concentric Analgesics and its pipeline drug CA-008 in post-surgical pain with an FDA Breakthrough Therapy designation (BTD). ... The Breakthrough Therapy designation is based on phase Ib placebo-controlled clinical

More from news
Approximately 1 fully matching, plus 105 partially matching documents found.

Latest Intelligence

Bluebird Bio: on the cusp of a gene therapy revolution

Bluebird’s four breakthrough candidates. In addition to the two LentiGlobin-based treatments, the company also has its Lenti-D product for patients with cerebral adrenoleukodystrophy (CALD), a rare, serious and ... There is no question that these
Deal Watch February 2017

IMMU-132 has FDA Breakthrough Therapy designation for the treatment of patients with TNBC who have failed prior therapies for metastatic disease and also has Fast Track status and orphan designation
Deal Watch January 2016

32, 000. Seres Therapeutics/ Nestle Health Science. Collaboration. Rights to market products including SER 262 (p1 for Clostridium difficile), 287, 301 and 109 (SER 109 has breakthrough therapy designation); includes $120m
Creating a 21st century life sciences ecosystem

Part of the scheme involves a new 'promising innovative medicine' designation - similar to the FDA's breakthrough designation - the first of which have started to be awarded.
Pharma deals during October 2014

Imbruvica was one of the first products to gain approval via the breakthrough designation pathway and has European approval for use in mantle cell leukaemia and chronic lymphocytic leukaemia.

More from intelligence
Approximately 0 fully matching, plus 6 partially matching documents found.

Latest from PMHub

The Heart of the Matter 7: Reality Dawns

At Amgen, our CfOR infrastructure has helped us use RWE to achieve orphan drug designation. ... Similarly, we also leveraged real-world historical comparator data to mazimise a first-to-market opportunity with a breakthrough therapy designation, priority

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Digital Manager, London – Healthcare Brandcomms, Medcomms, PR: Excellent package

Director, Market Access / HEOR - North-West: Negotiable

Senior Systematic Review Analyst - Oxford: Negotiable

Consultant Health Economics - London / Oxford: Negotiable

Freelance Account Manager / Senior Account Manager - Medical Edu...: £300 per day

Senior Medical Writer (Remote Working): Competitive Salary Offered

Senior Medical Writer: Great salary and benefits

Chief Medical Writer, Medical Communications, London, up to £90K...: up to £90K

Associate Director, Market Access & HEOR – North-West: Negotiable

SENIOR MEDICAL WRITER IN ONCOLOGY: Up to £60, 000.00 pension bonus

SAM – Health Behaviour/ Patient Adherence Healthcare Agency: Salary TBC

Account Director: £48, 000 - £60, 000

Medical Writers: Competitive Salary and Benefits

Senior Account Manager- Central Oxford and Abingdon: Negotiable

Senior Medical Writer: Competitive Salary

Account Manager, Healthcare Communications: £32, 000 - £40, 000 bonus benefits

Project / Account Manager (Medical Education): Salary TBC

Scientific Director / Editorial Team Leader: Great salary and benefits

Associate Editorial Director – Med Comms – London: Salary TBC

Associate Director: £75, 000-90, 000

New Business Director - PR: Competitive Salary and benefits

Programme Director, Healthcare PR, Highly competitive package: Highly Competitive package

Events Manager – Med Comms – Surrey: Salary TBC

Medical Writer – Health Behaviour/ Patient Adherence Agency: Salary TBC

Senior Account Manager: Negotiable

Subscribe to our email news alerts

PMHub

Add my company

M3 (EU)

M3 was founded in 2000 with the goal of changing the world of medicine through making full use of the...

Latest intelligence

World Diabetes Day: Interaction and impact of diabetes on mental health: For World Diabetes Day on the 14th November 2018, Nisha Shahrukh - Medical Writer at Mednet Group has written an article depicting the impact diabetes has on mental health. Including...
Innovation in merger control and the impact on the pharmaceutical sector: Is focusing on pipeline products enough to assess regulatory risks?...
Nudge-nudge, think-think: Chris Ross examines the personal complexities of human behaviour – and explains why fun, emotion and peer endorsement could be key to designing effective behavioural change programmes...